BANCO SANTANDER S.A. (SAN)
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
📉 **NEGATIVE** • Medium confidence analysis (63%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (16%) **Content type:** Clinical